The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model by Kucuk, Adem & Ozturk, Hulya
  
    
Exp Biomed Res 2019; 2(2):50-61                                                DOI: 10.30714/j-ebr.2019250350                           
                                                                                                                                 
                             Research article 
  
The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 
inhibitor celecoxib on liver damage in an experimental cholestasis model  
 
Adem Kucuk1, Hulya Ozturk2 
1Department of Pediatric Surgery, Duzce Ataturk State Hospital, Duzce, Turkey 
2Department of Pediatric Surgery, Bolu Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey 
 
A BST R AC T  
 
Aim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. 
Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for 
cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic 
liver diseases caused either by viruses or toxins. The present study was conducted to investigate the 
effects of UDCA and the selective COX-2 inhibitor celecoxib on inflammation and fibrogenesis in a 
rat model of cholestasis induced by bile duct ligation (BDL).  
Methods: Fifty Sprague–Dawley rats that underwent common BDL for 21 days were assigned to one 
of five treatment groups (sham-operation, BDL, daily UDCA treatment following BDL, daily 
celecoxib treatment following BDL, and daily celecoxib and UDCA combination treatment following 
BDL). Serum and liver samples were collected after 21 days. Fibrosis, ductular proliferation, and 
portal inflammation were scored in liver samples. Liver function tests were evaluated. 
Results: In comparison with the control group, the BDL group showed hepatic damage as evidenced 
by elevation in serum biochemical and histological changes such as ductular reaction, fibrosis, and 
inflammation. These pathophysiological changes were attenuated by chronic UDCA and selective 
COX-2 inhibitor celecoxib supplementation.  
Conlusion: Our findings indicate that the addition of Celecoxib to UDCA reduces liver inflammation 
and fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases. The 
beneficial effects of chronic UDCA and Celecoxib supplementation may be associated with their 
potential cytoprotective, anti-oxidative and anti-inflammatory effects. 
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Introduction 
Extrahepatic and intrahepatic biliary disorders 
can occur in newborns and adults for different 
reasons. Congestion and interruption can be 
anywhere from the porta to the duodenum. 
Biliary atresia is the most common cause in 
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neonatal period [1]. The incidence is about is 
1/8000 - 1/15000 worldwide [2, 3].  
In clinical and experimental studies, chronic 
obstructive jaundice has been shown to lead to 
the complete closure of the extrahepatic biliary 
tree by causing progressive inflammation and 
sclerotic reactions and fibrosis in the liver [4]. 
In untreated babies, it results in death at an 
average of 8 months. The main factors causing 
the development of fibrosis in the liver have 
been shown to include portal and systemic 
endotoxemia, balance disorder in oxidative-
antioxidant systems, and increase in the release 
of TNF-α, prostaglandins and cytokines in 
lipid peroxidation [5, 6]. It has been shown that 
liver damage can be reduced by using different 
drugs such as glucocorticoids, 
ursodeoxycholic acid (UDCA), glutamine, 
phenobarbital, cyclooxygenase-2 (COX-2) 
inhibitors, and curcumin to prevent these 
reported effects [5]. 
The aim of this study was first to induce 
chronic obstructive jaundice in prepubertal rats 
and to investigate the damage of this 
obstruction on the liver. Additionally, the 
study was designed to determine the role of 
COX-2 inhibitors and UDCA, which have 
been shown to have positive effects in the light 
of previous studies, in the prevention of these 
adverse effects in the liver when used alone 
and in combination. 
 
Methods  
The study was approved by the Duzce 
University Animal Research Local Ethics 
Committee (2010/04) and was carried out in 
Duzce University Experimental Animals 
Application   and   Research   Center. 
Extrahepatic biliary tract (EHBT) obstruction 
was performed using 50 prepubertal Sprague-
Dawley male rats weighing between 120 and 
220 grams. The rats were fed with standard 
feed and city water before and after the 
procedure. 
 
Experimental Protocol 
Ketamine hydrochloride (Ketalar®, 
Eczacibasi, Istanbul/Turkey) (25mg/kg, i.m.) 
was used as preanesthetic, and 
ketamine+xylazine hydrochloride were used 
for sedation (Rompun® 23.3 mg/ml, Bayer, 
Germany), (10 mg/kg and 3mg/kg, 
respectively, i.p.); buprenorphine (Tengesic® 
0.3 mg, Schering, Germany, 0.1-0.05 mg/kg, 
s.c.) was used for the analgesia. 
The abdominal skin of the rats was shaved, and 
laparotomy was performed with a midline 
incision under sterile conditions. Experimental 
cholestasis model was performed as previously 
described by Criado et al., and experimental 
groups were created [7]: 
Group 1 (Sham-Control group, n = 10): By 
performing laparotomy, EHBT was freed only 
from the surrounding tissues and the abdomen 
was closed.  
Group 2 (Group without medication, n = 10): 
EHBT was released from the surrounding 
tissues by laparotomy and was cut by 4/0 silk, 
and the abdomen was closed. 
Group 3 (2.5 g/kg UDCA-receiving group, n = 
10): EHBT was released from the surrounding 
tissues by laparotomy, was cut with 4/0 silk, 
and the abdomen was closed. UDCA (2.5 g/kg) 
was given using gavage tube for 21 days. 
Group 4 (30 mg/kg COX-2 inhibitor group, n 
= 10): Laparotomy was performed to free 
EHBT from the surrounding tissues, EHBT 
was cut with 4/0 silk, and the abdominal wall 
was closed. The COX-2 inhibitor celecoxib (30 
mg/kg) was administered by gavage tube for 
21 days. 
Group 5 (2.5 g/kg UDCA acid and 30 mg/kg 
COX-2 inhibitor group, n = 10): EHBT was 
released from the surrounding tissues by 
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laparotomy, was cut with 4/0 silk, and the 
abdominal wall was closed. UDCA (2.5 g/kg) 
and COX-2 inhibitor (30 mg/kg) were 
administered by gavage tube for 21 days. 
During the 3-week follow-up period, four rats 
died in each of Groups 1 (control) and Group 2 
(EHBT obstruction), while one rat died in each 
of Groups 3 (UDCA) and Group 4 (COX-2 
inhibitor), while no rats died in Group 5 rats 
(UDCA and COX-2 inhibitor combination). 
All studies were completed with ten rats per 
group, with additional rats added to replace 
those that died during the follow-up period. 
Additional rats underwent the same 
experimental procedures.  
In all groups, weight measurements were made 
before and three weeks after the procedure. 
Blood samples were obtained from the 
abdominal aorta for alkaline phosphatase 
(ALP), gamma glutamyl transferase (GGT), 
total bilirubin (TB), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and 
total protein (TP) measurements at three weeks 
using a similar anesthesia protocol; then, rats 
were sacrificed by cannulation, and liver 
samples were taken for histopathological 
evaluation. Approximately 3-4 ml of blood 
from the abdominal aorta were taken into 
heparinized tubes. Blood was centrifuged to 
obtain plasma, and ALP, GGT, total bilirubin, 
AST, ALT and total protein values in plasma 
were measured by using Roche HITACHI 
Cobas 6000, a standard autoanalyzer for 
biochemical studies by the enzymatic 
colorimetric method. 
Histopathological study was performed on 50 
liver tissue samples taken from all rats in all 
five groups by hepatectomy. Liver tissues were 
fixed in 10% formalin. Sections from these 
blocks were stained with Hemotoxylin-Eosin 
(H&E) and Masson’s trichrome for fibrosis. 
Presence of fibrosis, ductal proliferation, focal 
duct cholestasis, portal tract expansions, portal 
inflammation, polymorphonuclear leukocytes 
(PNL), and hepatocyte necrosis in the sections 
were examined. Histopathological evaluation 
was performed with a micrometer inserted 
objective (x200 magnification, Nikon Eclipse 
80i) or light microscopy (x100 magnification, 
Nikon Eclipse 80i) in 10 different areas. 
 
Statistical analysis 
Data obtained in this study were compared 
using SPSS (Statistical Package for Social 
Scienses) 10.0 statistical program. Values are 
shown as mean ± SD (Standard Deviation). 
One-Way ANOVA with post hoc Tukey b test 
was used for the evaluation of weight, 
biochemical results and histopathological 
results between groups, and Kruskal–Wallis 
test was used for the comparison of the 
parameters that did not show normal 
distribution and Mann–Whitney U test was 
used to determine the statistically different 
groups. The difference was considered 
significant when the p value was less than 0.05. 
 
Results 
After 21 days of follow-up, Groups 2, 3, 4, and 
5, all of which had undergone EHBT 
obstruction, were found to have significantly 
increased weight loss compared to the control 
group (p <0.05). In Group 2, rats lost more 
weight than the rats in Groups 3, 4, and 5 (p 
<0.05). In Group 5, rats lost less weight than 
the rats Groups 3 and 4 (p <0.05) (Table 1). 
The evaluated biochemical comparisons of the 
groups are presented in Table 2. According to 
this, ALP, GGT, TB, AST, ALT and TP values 
were found to be higher in all groups with 
ligation compared to the control group (p 
<0.05). ALP, GGT, AST and ALT values of 
Groups 3, 4, and 5 were significantly lower 
than the values of Group 2 (p <0.05). TP 
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values were significantly higher in Group 3 
compared to Groups 2, 4, and 5 (p <0.05). 
GGT and AST values of Group 4 were found 
to be lower compared to Groups 3 and 5 (p 
<0.05). The TP values of Group 5 were found 
to be significantly lower compared to Group 4 
(p <0.05). 
 
Table 1. Average weights of the rats before 
and after the EHBT obstruction. 
 
 
 
 
 
 
 
 
 
 
 
 
EHBT: Extrahepatic biliary tract  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathological examination revealed no 
histopathological and morphological 
abnormalities in H&E and Masson's trichrome 
staining in the control group (Figure 1A, B). 
The histopathological examination of liver 
tissues from Group 2 rats showed fibrosis, 
ductal proliferation, focal ductal cholestasis, 
portal tract expansion, portal inflammation, 
PNL, and hepatocyte necrosis. Connective 
tissue increase was detected in the portal and 
periportal area in Masson's trichrome staining 
(Figure 2A, B). In the histopathological 
examination of the liver tissues of Group 3 rats, 
we detected less proliferation and 
inflammatory cell infiltration sites in the portal 
and periportal biliary ducts. Masson's 
trichrome staining showed less deposition of 
connective tissue in the portal and periportal 
area (Figure 3A, B). In histopathological 
examination of liver tissues of Group 4 rats, 
decreased proliferation and inflammatory cell 
infiltration areas were detected in the portal 
and periportal biliary ducts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        Kucuk et al.  Exp Biomed Res 2019; 2(2):50-61 
   
 
54 
 
Masson's trichrome staining showed less 
accumulation of the connective tissue in the 
portal and periportal area (Figure 4A, B). 
When the histopathological findings of Group 
5 rats were  compared  to  those   of  Group  2,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
there was a significantly decreased 
proliferation in portal and periportal biliary 
ducts and a lesser degree of reduction in 
inflammatory cell infiltration and a slight 
decrease of fibrosis areas (Figure 5A, B). 
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The evaluated histopathological comparisons 
of the groups are presented in Table 3. There 
was a statistically significant difference 
between Groups 2, 3, 4, and 5 and Group 1 in 
terms of fibrosis, ductal proliferation, focal 
ductal cholestasis, portal tract expansion and 
portal inflammation (p <0.05). The amount of 
hepatocyte necrosis was significantly higher in 
Groups 2 and 3 compared to Group 1 (p 
<0.05). No significant difference was found 
between Groups 4 and 5 and Group 1 (p> 
0.05). A statistically significant difference was 
found in the comparison of Groups 4 and 5 
with Group 2 in terms of focal ductal 
cholestasis (p <0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly, there was a statistically significant 
difference between Group 5 and Group 2 in 
terms of ductular proliferation (p <0.05). In 
terms of portal inflammation and PNL, a 
statistically significant difference was found 
between Groups 3, 4, and 5 and Group 2 (p 
<0.05). There was a statistically significant 
difference between Group 5 and Group 3 in 
terms of PNL (p <0.05). In terms of hepatocyte 
necrosis, a statistically significant difference 
was found in the comparison of Groups 3, 4, 
and 5 with Group 2 (p <0.05). 
 
Discussion 
Enterohepatic circulation of bile acids allows 
the absorption of fats and fat-soluble vitamins 
from the gut and eliminates metabolic by-
products such as cholesterol, toxins and 
bilirubin from the liver. Normal bile formation 
is due to the transcriptional coordination 
regulated    by       both        posttranscriptional  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mechanisms and nuclear receptors, together 
with the appropriate function of membrane 
transport systems in the enterohepatic pathway 
such as hepatocytes, bile duct epithelial cells 
(cholangiocytes), and enterocytes [8]. 
Cholestasis, known as a breakdown of the 
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biliary stream or flow, causes hepatotoxicity 
due to the accumulation of bile acids and other 
toxins in the liver and damage to the 
intracellular compartments and cell 
membranes. The most common causes of 
cholestasis in the neonatal period are biliary 
atresia and choledochal cyst. In addition, 
cholestasis is a component of many liver 
diseases such as cholelithiasis, cholestasis of 
pregnancy, primary biliary cirrhosis, and 
primary sclerosing cholangitis [9]. Cholestatic 
liver injury is also a major cause of chronic 
liver disease. Chronic retention of toxic bile 
acids is an important mechanism for cell 
toxicity, including oxidative stress, apoptosis, 
and fibrosis [10]. In histological analysis of 
liver sections rats that underwent BDL, bile 
duct proliferation, parenchymal necrosis, and 
inflammatory cell infiltration were found to be 
increased [11]. 
In rats that underwent EHBT ligation 
according to the method described by Criado 
et al. [7], there was an increase in biochemical 
values (ALP, GGT, TB, AST, ALT and TP) 
compared to the control group, and fibrosis, 
ductal proliferation, focal ductal cholestasis, 
portal tract expansion, portal inflammation, 
PNL increase, and hepatocyte necrosis were 
observed histopathologically in the liver. This 
model, which we applied, caused a stasis in the 
intrahepatic biliary tract and was evaluated as 
a suitable model. Similarly, biochemical 
values were found to be higher and 
histopathological changes were observed in 
Groups 3, 4 and 5, which had EHBT ligation 
and were treated with different drugs, 
compared to the control group. However, 
biochemical and histopathological results were 
found to be better in Groups 3, 4, and 5, which 
were treated with UDCA, the COX-2 inhibitor 
celecoxib and the combination of celecoxib 
and UDCA, respectively, than in group 2, 
which had only EHBT ligation. 
UDCA is an endogenous tertiary natural bile 
acid that normally constitutes 0.1-5% of the 
bile pool found in the human. UDCA is the 
only drug approved by the FDA for chronic 
cholestatic liver disease in the treatment of 
primary biliary cirrhosis, and its efficacy in the 
dissolution of cholesterol gallstones has been 
demonstrated [12]. It inhibits cholesterol 
absorption in intestines, and cholesterol 
secretion and cholesterol crystal formation in 
bile. UDCA protects the lipid layer of the liver 
cell membrane against the toxic effect of 
hydrophobic bile salts (cytoprotective effect) 
[13]. It prevents the inclusion of bile acids such 
as kenodeoxycholic acid and cholic acid in the 
enterohepatic circulation and constitutes 40% 
to 55% of total bile salts, resulting in the 
formation of copious amounts bile rich in 
bicarbonate (cholehepatic shunt) [14]. Oral 
administration of various bile salts to 
obstructive jaundice rats eliminates 
endotoxemia by reducing intestinal absorption 
of endotoxin. UDCA has a hepatoprotective 
effect by protecting hepatocytes against 
oxidative damage in obstructive jaundice rats. 
It was also claimed that bile salts have lytic 
effects on the cell walls of intraluminal 
bacteria [15]. UDCA reduces excess HLA-
Class I antigen expression in hepatocytes, and 
HLA-Class II antigen expression in biliary 
epithelium [16]. Abdelmalek et al. gave 
UDCA to a patient with steatohepatitis for one 
year. The patient’s liver function tests 
improved, were elevated again after 
discontinuation, and subsequently decreased 
again when the drug was reinitiated [17]. 
Laurin et al. gave 13-15 mg/kg/day UDCA to 
24 non-alcoholic liver patients for one year and 
found a significant reduction in steatosis, ALT, 
AP, and GGT levels at the end of treatment. 
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They thought that there was an association 
between the improvement and the membrane 
stabilizing and cytoprotective effects of UDCA 
[18]. In a study by Barone et al. with partial 
bile duct ligation in rats, UDCA increased 
cholangiocyte proliferation; they suggested 
that this supports the use of UDCA in the 
treatment of cholestatic chronic liver diseases. 
They reported that UDCA reduced liver 
damage and apoptosis and delayed ductopenic 
stage by stimulation of proliferation [19]. 
Experimental cholestasis models and 
hepatocytes in which animals are treated with 
toxic bile acids have been reported to have 
decreased liver glutathione (GSH) levels. 
Decrease in GSH levels endangers antioxidant 
defense and contributes to injury. In other 
studies, a decrease in glutamylcysteine ligase 
(GCL) activity has been shown [10]. It was 
reported that UDCA inhibited the decrease of 
GCL levels during chronic cholestasis and 
increased GCL levels [20]. In an experimental 
study conducted by Yang et al. [10], it was 
suggested that UDCA maintains GSH levels 
and prevents liver damage. In the study by 
Kitani et al., it was shown that there was a 
significant reduction of microvascular fat 
formation in hepatocytes and a decrease in 
AST, ALT, and GGT levels after UDCA was 
given to the group of animals with obstructive 
jaundice [21]. Beuers et al. [22] suggested that 
the beneficial effect of UDCA in cholestasis-
induced rats may be due to calcium-dependent 
stimulation of vesicular exocytosis by UDCA. 
Al-Hathlol et al. [23] found cholestasis in 13 
babies with very low birth weight, most with 
necrotizing enterocolitis when the babies were 
about 36 days old, and observed a significant 
decrease in bilirubin levels with treatment of 
UDCA for 3 months. 
The enzyme cyclooxygenase (COX) has been 
shown to increase as a result of active 
inflammation in the case of chronic 
cholestasis. The enzyme cyclooxygenase has 
two isoforms: COX-1 and COX-2. COX-1 is 
structurally deposited, i.e. it is always present 
because of its continuous synthesis in the cells 
in which it is produced. COX-2 increases as a 
result of inflammation, mitogenic stimuli, and 
various growth factors. Induction of the COX-
2 enzyme results in prostaglandin synthesis in 
inflamed tissues. In the development of early 
fibrosis in rats, vasoconstrictive endothelin 1 
(ET-1) and thromboxane A2 (TXA2) in 
Kupffer cells play an important role in the 
development of hepatocellular injury and 
portal hypertension. COX-2 is one of the key 
enzymes involved in the increase of ET-1 and 
TXA2 during prostaglandin synthesis [24]. 
This is related to the fact that COX-2 is a 
regulatory enzyme that is involved in the 
synthesis of prostaglandins and their 
metabolites in inflammation, cellular 
proliferation, anti-apoptosis, cell growth, and 
angiogenesis. Therefore, inhibition of COX-2 
has been a pharmacological target to reduce 
prostaglandin production in cases of chronic 
inflammation and fibrosis. The antifibrotic 
effect of COX-2 inhibitors has been previously 
reported in several in vivo and in vitro 
experimental studies such as renal interstitial 
fibrosis and desmoplasia. In addition, selective 
COX-2 inhibitors are known to play a role in 
the liver as an antifibrotic agent [25-27]. It has 
been suggested that cholestasis causes COX-2 
accumulation in the liver of rats that underwent 
BDL and that the selective COX-2 inhibitor 
meloxicam reduces liver fibrosis caused by 
BDL. This effect of meloxicam was associated 
with a reduction of cyclooxygenase activity in 
the liver and a decrease in liver TGF-β1 [28]. 
Yu et al. [29] demonstrated the role of 
celecoxib in cholestatic liver fibrosis using 
morphological and molecular biology data in 
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their study of celecoxib in rats with biliary tract 
ligation. They reported that celecoxib was 
protective against liver inflammation in the 
early stages in rats that underwent BDL, but 
not on liver fibrosis. 
In our study, it was found that ALP, GGT, AST 
and ALT values of Groups 3, 4 and 5, which 
we gave drug treatment, decreased 
significantly compared with Group 2, and liver 
function was better. The TP values of Group 3, 
which received UDCA therapy, were found to 
be lower compared to TP values of Groups 2, 
4, and 5, and the difference was statistically 
significant. It was determined that GGT and 
AST values of Group 4, which was treated with 
celecoxib, were lower in comparison with 
GGT and AST values of Groups 3 and 5, and 
the difference was statistically significant. The 
TB values of Group 5 rats treated with the 
combination of UDCA and celecoxib were 
found to be significantly lower in comparison 
with Group 4. The histopathological 
examination of all groups with EHBT ligation 
revealed significant changes in ductular 
proliferation, focal ductal cholestasis, portal 
tract expansion, portal inflammation, and 
increase in polymorphonuclear leukocytosis, 
hepatocyte necrosis, and fibrosis compared 
with control group (Group 1). However, it was 
found that hepatocyte necrosis of Groups 4 and 
5 was present compared to Group 1, although 
the increases were not significant. In terms of 
hepatocyte necrosis, Groups 2 and 3 were 
higher compared to Group 1. Although the 
results of both the biochemical tests and the 
histopathological examination of all groups 
that received a drug treatment were better 
compared to Group 2, the results of both the 
biochemical and histopathological evaluations 
were found to be more positive in the group 
receiving celecoxib. More favorable results in 
histopathological examination of liver tissues 
were observed in Group 5 rats, where the 
additive effects of both drugs were obtained 
with the combination of a COX-2 inhibitor and 
UDCA. These positive effects on the liver 
suggest that these may be the result of a 
combination of the cytoprotective and 
antioxidant effects of UDCA and the anti-
inflammatory, cell proliferation-inhibiting, 
and anti-apoptotic effects of the COX-2 
inhibitor celecoxib. 
 
Conclusion 
Our findings suggest that the addition of 
celecoxib to UDCA may be an effective 
complementary treatment for cholestatic 
diseases by reducing inflammation and fibrosis 
in the liver. The combination of celecoxib and 
UDCA reduced liver damage in rats that 
underwent biliary tract ligation. Clinically, 
COX-2 and UDCA can be used separately or 
together to prevent liver fibrosis in the 
preoperative period. However, further studies 
on this issue are necessary.  
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